** Shares of Gyre Therapeutics GYRE.O down 17.5% post-market to $9.25 as co seeks equity raise
** San Diego-based biotech commences stock offering; deal size not disclosed
** It intends to use net offering proceeds to fund advancement of Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis ("MASH”)-associated liver fibrosis in the U.S., for R&D, and manufacturing among other uses
** Jefferies lead bookrunner for offering
** Co also says F351 met primary endpoint in pivotal Phase III evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China
** With ~93.8 mln shares outstanding, co has ~$1bln market cap
** GYRE finished up 8.1% at $11.21 on Thurs, cutting YTD loss to ~7%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。